Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

Rid­ing on the mo­men­tum of two li­cens­ing deals, Har­bour Bio­Med now has $85 mil­lion to ad­vance its fresh­ly beefed up pipeline.

GIC — Sin­ga­pore’s sov­er­eign wealth …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER